Copertina

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
di: Chay Ngee Lim, et al.
Pubblicazione: (2025)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
di: Andrew Blumenfeld, et al.
Pubblicazione: (2024)

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States
di: Noah Rosen, et al.
Pubblicazione: (2025)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
di: Susan Hutchinson, et al.
Pubblicazione: (2026)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
di: Dawn C. Buse, et al.
Pubblicazione: (2026)

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
di: Hedda S. Riise, et al.
Pubblicazione: (2026)

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
di: Richard B. Lipton, et al.
Pubblicazione: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
di: Gabriel Paiva da Silva Lima, et al.
Pubblicazione: (2025)

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study
di: Shivang Joshi, et al.
Pubblicazione: (2026)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open‐label, clinical trial
di: Omar A. Almohammed, et al.
Pubblicazione: (2024)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)

Real‐world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program
di: Idris Demirsoy, et al.
Pubblicazione: (2025)

Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study
di: Tara L. Sharma, et al.
Pubblicazione: (2024)

Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study
di: Richard J. Bertz, et al.
Pubblicazione: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Plain Language Summary Publication: Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open‐label, clinical trial
di: Omar A. Almohammed, et al.
Pubblicazione: (2024)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
di: Stephen D. Silberstein, et al.
Pubblicazione: (2024)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
di: Dawn C. Buse, et al.
Pubblicazione: (2025)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
di: Rebecca Lindsay, et al.
Pubblicazione: (2024)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
di: Devin Teichrow, et al.
Pubblicazione: (2026)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Prevalence and burden of migraine in the United States: A systematic review
di: Fred Cohen, et al.
Pubblicazione: (2024)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings
di: Fred Cohen, et al.
Pubblicazione: (2024)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
di: Christopher C. Anderson, et al.
Pubblicazione: (2024)

Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study
di: E. S. Hoogeveen, et al.
Pubblicazione: (2024)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States
di: Shivang Joshi, et al.
Pubblicazione: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
di: Julia Peris‐Subiza, et al.
Pubblicazione: (2025)